Important note

This AI stock analysis for Calidi Biotherapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Calidi Biotherapeutics - AI Stock Analysis

Analysis generated November 27, 2024

Calidi Biotherapeutics is a cutting-edge biotech company that is focused on the development of novel cancer therapies. It's a leader in the field of oncolytic virus-based immunotherapies, with a strong emphasis on leveraging the power of the immune system to combat cancer. The company is known for its innovative approaches and has attracted significant attention from both researchers and investors. However, it is important to evaluate their financial performance and market sentiment to gauge investment potential.

Fundamental Analysis

Revenue for the last quarter was 0. This is equal to the revenue of the quarter before it, showing stability. Additionally, it is also equal to the revenue of the same quarter last year, indicating a consistent yet stagnant revenue stream. This raises questions about the company's ability to generate revenue, but could indicate a focus on R&D and long-term projects.

Net income for the last quarter was $5.1M. This is an increase of 12.36% compared to the quarter before it, a positive sign of short-term growth. However, compared to the same quarter last year, there is a decrease of 149.70%, which is a cause for concern and warrants deeper investigation into the reasons behind this sharp decline.

EBITDA for the last quarter was $5.2M. This represents a decrease of 2.31% compared to the quarter before it, indicating a need for concern over recent operations. Nonetheless, compared to the same quarter last year, there is an increase of 26.61%, suggesting healthy year-over-year growth, indicating operational improvements.

Technical Analysis

Today's stock price is $1.93. This marks an increase of 77.06% compared to a month ago, indicating a positive short-term trend. However, compared to a year ago, there is a significant decrease of 89.28%, signaling long-term concerns. The trend appears to be bearish.

The current SMA10 (Simple Moving Average for 10 days) is 2.15, slightly lower than the previous SMA10 of 2.18. This suggests a potential downward trend in price movement. The Relative Strength Index (RSI) is 62.7, indicating neutral market conditions.

Alternative Data Analysis

Job postings and employee sentiment provide additional insights. Calidi Biotherapeutics has 2 open positions, a number that remained steady over the last couple of months. This suggests a stable yet cautious approach to expansion.

Employee sentiment is highly positive, with an estimate of 100% of employees having a positive outlook on the company's future, a very encouraging sign.

Customer acquisition metrics show an estimated 2,000 visitors to their webpage with no significant increase or decrease in recent months. On social media, Calidi Biotherapeutics has 71 followers on Twitter, an increase of 15% in the last couple of months, indicating growing interest and engagement.

Finally, AltIndex's AI-powered analysis scores Calidi Biotherapeutics with an AI score of 75, suggesting a "buy" signal based on a combination of fundamental, technical, and alternative data.

Conclusion and Recommendation

Based on the analysis of Calidi Biotherapeutics' financial performance, technical indicators, and alternative data, it is clear that the company presents a mixed investment case. The stagnation in revenue and the significant decline in net income year-over-year are areas of concern. However, positive employee sentiment and a healthy year-over-year EBITDA increase are strong indicators of potential future growth. Additionally, the sizeable short-term stock price increase and a very positive AI scoring point towards an upward trend in the short term.

Given the mixed but generally positive indicators, a considered approach would be to "hold" or cautiously "buy" shares of Calidi Biotherapeutics, keeping a close watch on revenue growth and long-term strategic developments.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.